Allograft dendritic cell (DC) content has been identified as a predictor of relapse and event-free survival after allogeneic bone marrow transplantation. However, the prognostic importance of DCs has not been evaluated in the setting of autologous hematopoietic stem cell transplantation (HSCT). We prospectively determined pretransplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large Bcell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT. Pre-transplant DCs were measured in the collected stem cell products and were therefore indicative of cell numbers infused directly into patients; post transplant analysis of DCs was performed on the peripheral blood of patients 6 weeks after the infusion of autologous stem cells. Higher pre-transplant levels of DC1 cells and total DCs were significantly associated with improved survival. Similarly, greater post transplant levels of total DCs and both subsets were significantly associated with survival. These findings suggest a relationship between DC reconstitution and survival following autologous HSCT for DLBC NHL. Strategies to increase autograft DC content or accelerate DC recovery after autologous HSCT might improve outcomes in this setting.
Allograft dendritic cell (DC) content has been identified as a predictor of relapse and event-free survival after allogeneic bone marrow transplantation. However, the prognostic importance of DCs has not been evaluated in the setting of autologous hematopoietic stem cell transplantation (HSCT). We prospectively determined pretransplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large Bcell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT. Pre-transplant DCs were measured in the collected stem cell products and were therefore indicative of cell numbers infused directly into patients; post transplant analysis of DCs was performed on the peripheral blood of patients 6 weeks after the infusion of autologous stem cells. Higher pre-transplant levels of DC1 cells and total DCs were significantly associated with improved survival. Similarly, greater post transplant levels of total DCs and both subsets were significantly associated with survival. These findings suggest a relationship between DC reconstitution and survival following autologous HSCT for DLBC NHL. Strategies to increase autograft DC content or accelerate DC recovery after autologous HSCT might improve outcomes in this setting. Dendritic cells (DCs) are class II MHC-bearing antigenpresenting cells necessary for priming of naı¨ve T cells. At least two distinct subsets of circulating DCs have been described, which develop independently from a common precursor cell. [1] [2] [3] DCs that express CD11c (DC1s) have myeloid morphology and, when stimulated with tumor necrosis factor, produce high levels of interleukin-12 causing antigen naı¨ve CD4 þ CD45RA þ T-cell differentiation to Th1 cells. 2, 3 A second population of circulating DCs known as plasmacytoid DCs (DC2s) has a CD11c À /CD123 bright immunophenotype; current evidence suggests they are direct precursors of lymphoid DCs and initially serve to stimulate antigen naı¨ve CD4 þ CD45RA þ T cells to differentiate into Th2 cells. 4, 5 The antigen presentation function of DCs dictates their essential role in the development of specific antitumor T-cell responses. 6 Clinical immunotherapy trials have employed autologous DCs in vaccines directed at a variety of tumor antigens. 4 However, the relevance of DC biology in the setting of hematopoietic stem cell transplantation (HSCT) has received limited attention. A recent clinical report suggests that patients undergoing allogeneic bone marrow transplantation who receive higher numbers of DC2 in the allograft have a lower incidence of chronic graft-versus-host disease (cGVHD) and an increased incidence of disease relapse. 7 In patients undergoing autologous HSCT, however, the significance of DC levels has not been examined. Previous studies measuring DC levels in autologous HSCT patients did not relate their findings to transplant outcomes. [8] [9] [10] We previously described the DC content of mobilized peripheral blood progenitor cells (PBPC) for autologous transplantation. 11 The present study was conducted to evaluate the prognostic value of DC levels pre-and post transplant in patients undergoing autologous HSCT for relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma (DLBC NHL).
Patients and methods
Adult patients with relapsed or refractory DLBC NHL who underwent autologous HSCT at the Cleveland Clinic Foundation between 7/2000 and 3/2004 were offered study participation. All patients were treated on protocols approved by the Institutional Review Board of the Cleveland Clinic Foundation and gave written informed consent.
PBPC mobilization regimen
All patients received G-CSF alone or G-CSF plus etoposide for PBPC mobilization. G-CSF 10 mg/kg/day subcutaneously was administered to all patients. Those receiving G-CSF alone began leukapheresis on day 5 of administration. Patients receiving the combination mobilization regimen also received etoposide 2 gm/m 2 on day 1 of G-CSF administration, and leukapheresis was begun once total WBC recovery was 41000/mm 3 .
PBPC collection and processing
PBPC collection was performed with a COBE Spectra leukapheresis machine (COBE, Denver, CO, USA). Patients underwent apheresis for at least 2 days, with a minimum collection goal of 2.0 Â 10 6 CD34 þ cells/kg. Apheresis continued for up to 5 days, or when 7.0 Â 10 6
CD34
þ cells/kg were collected, whichever came first.
DC determination by flow cytometry
Pre-transplant DC analyses were performed on samples of the collected apheresis product, thus representing DCs that were infused into patients. Samples for DCs post transplant were obtained from peripheral blood of patients approximately 6 weeks after the infusion of autologous PBPC. Fresh PBPC products were processed for flow cytometry to quantitate myeloid (CD11c þ ) and lymphoid (CD123 þ ) subclasses of peripheral blood DCs. Since neither CD123 nor CD11c are specific individual markers of DCs, a fourcolor flow cytometry assay was used with a gating strategy that employed a cocktail of antibodies to first separate neutrophils, monocytes, lymphocytes, and NK cells from basophils and DCs. Basophils were then distinguished from DCs based on the levels of HLA-DR expression: basophils lack HLA-DR expression, whereas this antigen is highly expressed on DCs. This assay utilized commercially available antibodies in a procedure optimized for flow cytometry by the manufacturer and has been previously described in detail. 11 
Statistical analysis
Categorical variables are summarized as frequency counts and percentages; continuous variables are summarized as the median and range. Overall survival was measured from the time of transplant until documented death or last patient contact. Recursive partitioning analysis for survival data was used to determine if cutpoints of pre-or post transplant DCs could be identified that correlate with survival; this was carried out using STREE software for censored survival data developed by HP Zhang and using the log-rank splitting method. 12 If cutpoints were identified, Kaplan-Meier survival curves were constructed and the log-rank test used to compare survival between the groups identified. All analyses were carried out using SAS s software. All statistical tests were two-sided, and Po0.05 was used to indicate statistical significance.
Results

Patients and clinical outcomes
A total of 49 (92.5%) patients received G-CSF and etoposide as a mobilization regimen and four received G-CSF alone. A median of three (range 2-8) leukapheresis sessions was performed for all patients and the median number of CD34 þ cells infused was 8.7 Â 10 6 /kg (range 2.0-42.8). In all, 52 (98%) of the patients received a combination preparative regimen consisting of busulfan, cyclophosphamide and etoposide, while one patient received busulfan alone. A total of 51 (96%) patients were sensitive to chemotherapy at the time of transplant. The median follow-up time for surviving patients was 13.5 months (range 1.3-33.3).
DC levels and survival analysis
All patients were evaluable for pre-transplant DC analysis. In total, 34 (64%) patients received follow-up care at our institution and were thus evaluable for post transplant DC analysis. Data on DC subsets are presented in Table 2 .
At the time of analysis, 39 patients (74%) were alive. Univariate analysis revealed that higher numbers of pretransplant DC1 and total DCs were associated with improved survival. Patients (n ¼ 16) with pre-transplant DC1 levels o4.00 Â 10 6 /kg were observed to have a median Prior radiotherapy 18 34 survival of 11.3 months; median survival was not reached in the group with DC1 levels X4.00 Â 10 6 /kg (P ¼ 0.041; Figure 1 ). Similarly, patients with pre-transplant total DC levels o9.10 Â 10 6 /kg were observed to have a median survival of 11.5 months, while median survival was not reached in the group with total DC levels X9.10 Â 10 6 /kg (P ¼ 0.022; Figure 2 ). Pre-transplant levels of DC2 cells were not found to correlate with overall survival (data not shown).
Post transplant levels of total DCs as well as DC1 and DC2 subsets were all found to be significantly associated with survival. The median survival for patients with DC1 levels o6.10 Â 10 6 post transplant was 8.6 months, whereas median survival was not reached in the patients with post transplant DC1 levels X6.10 Â 10 6 (P ¼ 0.028). For patients with DC2 levels o6.00 Â 10 6 post transplant, median survival was 14.6 months. Median survival was not reached in patients with post transplant DC2 levels X6.00 Â 10 6 (P ¼ 0.035). Finally, patients with post transplant total DC levels o14.00 Â 10 6 were observed to have a median survival of 11.3 months, while median survival was not reached in the group of patients with levels X14.00 Â 10 6 (P ¼ 0.039). In order to assess potential confounding by total CD34 þ counts, correlation between total CD34 þ and total as well as all DC subsets was calculated. No significant correlation was found (coefficient range -0.14 to 0.01; P-value range 0.33-0.97). To evaluate the possibility that DCs influence survival through an effect upon engraftment, we examined hematologic recovery and early mortality after autologous HSCT. When comparing patients having pre-transplant total DC levels o9.10 Â 10 6 with patients whose total DC levels were X9.10 Â 10 6 , there were no significant differences in platelet recovery (median 14 days vs 15 days), neutrophil recovery (median 10 days for each group), or mortality at 30 days (0% for each group) or 100 days (3.7 vs 7.7%; P ¼ 0.53) after autologous HSCT. Likewise, patients with pre-transplant DC1 levels o4.00 Â 10 6 were similar to patients with pretransplant DC1 levels X4.00 Â 10 6 with respect to platelet recovery (median 15 days vs 14 days), neutrophil recovery (median 10 days for each group), and early mortality (0% at 30 days for each group; 6.2 vs 5.4% at 100 days).
Discussion
We report that higher pre-transplant and post transplant levels of DCs are associated with improved overall survival in patients undergoing autologous HSCT for relapsed or refractory DLBC NHL. Of note, published data have demonstrated associations between clinical transplant outcomes and other defined cellular components of the transplanted autograft. Multiple studies document more rapid hematologic recovery in patients who receive higher doses of CD34 þ cells in their autografts. 13 Porrata et al 14 reported a significant prolongation of progression-free and overall survival in patients undergoing autologous HSCT for non-Hodgkin's lymphoma who received higher doses of lymphocytes in the autograft and were subsequently observed to have an absolute lymphocyte count of X500/ ml on day 15. Our preliminary findings support and expand this body of literature, providing the first evidence for an association between a specific cellular component of the autograft and subsequent survival following autologous HSCT. Recognition of such potential relationships will become increasingly important to the successful development of graft engineering strategies in HSCT. Although the total number of subjects was relatively small, the absence of correlation between total CD34 þ count and all DC subsets suggests DCs to be independent predictors of overall survival. However, our analysis Table 2 Total and dendritic cell (DC) subsets pre-and post transplant Dendritic cells predict survival in autologous HSCT R Dean et al cannot explain the basis for this association. Rather than influencing transplant outcomes directly, DC levels could conceivably be markers for disease biology, prior therapies, and general immune competence after transplantation. These variables should be considered in future studies analyzing pre-and post transplant DC levels in comparison with established prognostic factors for DLBC NHL patients undergoing autologous HSCT. It remains to be determined whether DC1 and DC2 subsets directly influence survival after autologous HSCT, and through what mechanism this occurs. Such an effect, if confirmed, would contrast with prior preclinical and clinical reports that suggest a differential effect of DC1 and DC2 on antitumor immunity. A recent trial of a pretransplant vaccine for AML patients undergoing autologous HSCT provides indirect evidence highlighting the role of DC1s in this setting. 15 By comparison, the potential value of DC2s in cancer immunotherapy remains unknown. 4 In vitro studies demonstrate that freshly isolated human DC2s are approximately half as potent as DC1s when used as allostimulators in mixed leukocyte reactions. 2 Moreover, in vivo mouse studies suggest DC2s may confer immunotolerance possibly by reducing IL-2 production from CD8T cells. 16 Accordingly, the tolerogenic potential of DC2s is supported by the clinical observation that increasing allograft DC2 doses were associated with inferior event-free survival, a lower incidence of cGVHD, and a higher incidence of relapse in allogeneic bone marrow transplant recipients. 7 Previous analysis at our institution demonstrates that DCs are differentially mobilized in patients receiving G-CSF alone compared to those receiving G-CSF plus etoposide; G-CSF alone mobilizes greater amounts of DC2s and higher ratios of DC2 to DC1 cells. 11 Taken together, our observations suggest a rationale for prospective studies to explore whether manipulating the DC content of the graft leads to more favorable clinical outcomes.
